The Claim
In individuals with MAPT gene mutations who develop tau pathology in the absence of amyloid-beta pathology, cerebrospinal fluid levels of phosphorylated tau are normal, indicating that phosphorylation of tau in cerebrospinal fluid is specifically dependent on the presence of amyloid-beta pathology and not solely on tau aggregation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with a genetic mutation that causes tau protein to clump in the brain but who do not have amyloid-beta plaques have normal levels of phosphorylated tau in their spinal fluid, showing that this specific tau modification requires amyloid-beta to occur.
See the scientific wording
Individuals with MAPT gene mutations who develop tau pathology without amyloid-beta pathology show normal levels of CSF phosphorylated tau, indicating that tau phosphorylation in CSF is specifically linked to amyloid pathology rather than tau aggregation alone.
When amyloid-beta builds up in the brain, it stresses neurons and causes enzymes to add extra phosphate groups to tau protein. This modified tau becomes soluble and leaks out of neurons into the fluid surrounding the brain. Without amyloid-beta, tau can clump together inside neurons but does not get phosphorylated or released into this fluid.
What the research says
1 studyPeople who have tau tangles in their brain from a genetic mutation but no amyloid plaques have normal levels of a specific tau protein in their spinal fluid — meaning that amyloid, not just tau tangles, is needed to make this signal go up.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.